PTC Therapeutics Highlights Duchenne Therapies Translarna and Emflaza in Corporate Report
Successful results of Translarna (ataluren) and Emflaza (deflazacort) therapies for Duchenne muscular dystrophy (DMD) are highlighted in the 2017 second quarter report by PTC Therapeutics. Orally-administered Translarna is for Duchenne patients to reduce the effect of nonsense mutations in the DMD gene that lead to a lack of…